Clinical trial
Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity…
NCT00191295 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00191295 |
|---|---|
| Title | Atomoxetine Versus Placebo in Children With Attention Deficit/Hyperactivity Disorder (ADHD) |
| Official title | A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Comparison of Fixed-Dose Ranges of Atomoxetine Hydrochloride in Child Outpatients With Attention-Deficit/Hyperactivity Disorder |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Attention Deficit Hyperactivity Disorder |
| Intervention type | Drug |
| Interventions | Atomoxetine, Placebo |
| Enrollment | 240 |
| Start date | Feb 1, 2005 |
| Completion | Sep 1, 2006 |
| First posted | Sep 19, 2005 |
| Last update posted | Nov 6, 2007 |
| Countries | Japan |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: